Hallway Conversation: Perampanel

Published Online: Tuesday, March 20, 2012
Follow Pharmacy_Times:
In this podcast, part of Epilepsy.com’s Hallway Conversations series, Joseph Sirven, MD, professor of neurology at Mayo Clinic Arizona and editor-in-chief of Epilepsy.com, interviews Gregory Krauss, MD, professor of neurology at Johns Hopkins Medical School, about the promising new antiepileptic drug (AED) perampanel.
 
Dr. Krauss explains that perampanel, the first drug in its class fully developed to treat epilepsy, targets the AMPA receptor, 1 of 3 receptors that help control neuronal excitability of the sort involved in seizure generation. He adds that the drug has a long half life of 70 hours, which means that it only has to be taken once a day. In addition, he notes that perampanel, which has not yet been approved by the FDA, has shown great promise in treating refractory epilepsy, although there have been some variations in trial results, particularly from centers where data may not have been accurately recorded.
 
To listen to the podcast, click here and scroll down to the October 24, 2011, episode.
Related Articles
The FDA today expanded the indication for perampanel hydrate (Fycompa) as an adjunctive treatment of primary generalized tonic-clonic seizures for patients aged 12 years or older with epilepsy.
Family planning is especially challenging for women with epilepsy.
Controlling seizures is critical for patients with epilepsy, but side effects of antiepileptic drugs are another tremendous concern.
Epilepsy has scores of factors, each leading to different treatment strategies and complicating the development of an evidence-based approach to seizure control.
Latest Issues
$auto_registration$